UBS O'Connor’s Haemonetics HAE Stock Holding History

UBS O'Connor’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-145,000	Closed	-$10.2M	–	972
2021 Q3	$10.2M	Buy	+145,000	New	+$9.15M	0.08%	109

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

LCP

LGT Capital Partners Pfaeffikon, Switzerland $1.88B AUM 20.37% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

UBS O'Connor's HAE Position: Q4 2021 in Review

UBS O'Connor sold out of Haemonetics (HAE) in Q4 2021, closing a stake of 145,000 shares — an estimated $10.2M sold.

UBS O'Connor first reported a position in HAE in Q3 2021 and held it in 1 quarter. The position peaked at $10.2M in Q3 2021. 257 funds tracked by Wall St. Rank hold HAE as of Q4 2021.

UBS O'Connor reported no remaining Haemonetics position as of Q4 2021 after selling out during the quarter.
UBS O'Connor sold 145,000 Haemonetics shares in Q4 2021, an estimated $10.2M.
UBS O'Connor first reported a position in Haemonetics in Q3 2021 and held it in 1 quarter.
UBS O'Connor's Haemonetics position peaked at $10.2M in Q3 2021.
257 funds tracked by Wall St. Rank held Haemonetics as of Q4 2021.

Based on UBS O'Connor's 13F filing for Q4 2021, filed 14 Feb 2022.